Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of DS-8201a (trastuzumab deruxtecan) in HER2-expressing Advanced Colorectal Cancer
2017-003466-28Phase 2Unknown
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2018
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate (ORR) per imaging assessment. Status: unknown.
02
Drugs
trastuzumab deruxtecan
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2017-003466-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003466-28.